102 related articles for article (PubMed ID: 9662994)
1. [Molecular mechanisms of prostatic oncogenesis].
Zezerov EG; Severin ES
Vestn Ross Akad Med Nauk; 1998; (5):29-35. PubMed ID: 9662994
[TBL] [Abstract][Full Text] [Related]
2. Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia.
Singer E; Linehan J; Babilonia G; Imam SA; Smith D; Loera S; Wilson T; Smith S
PLoS One; 2013; 8(6):e60562. PubMed ID: 23762225
[TBL] [Abstract][Full Text] [Related]
3. Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer.
Zenzmaier C; Sampson N; Plas E; Berger P
Prostate; 2013 Sep; 73(13):1441-52. PubMed ID: 23765731
[TBL] [Abstract][Full Text] [Related]
4. [IDENTIFICATION OF A NEW DIAGNOSTIC MARKERS OF PROSTATIC CANCER, USING NOTI-MICROCHIPS].
Vozianov SO; Kashuba VI; Grygorenko VM; Gordiyuk VV; Danylets RO; Bondarenko YM; Vikarchuk MV
Klin Khir; 2016 Apr; (4):54-7. PubMed ID: 27434957
[TBL] [Abstract][Full Text] [Related]
5. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.
Wang Z; Hu L; Salari K; Bechis SK; Ge R; Wu S; Rassoulian C; Pham J; Wu CL; Tabatabaei S; Strand DW; Olumi AF
J Pathol; 2017 Dec; 243(4):457-467. PubMed ID: 28940538
[TBL] [Abstract][Full Text] [Related]
6. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells.
Li W; Wu CL; Febbo PG; Olumi AF
Am J Pathol; 2007 Oct; 171(4):1189-98. PubMed ID: 17702894
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of human androgens and prostatic diseases.
Novelli G; Margiotti K; Sangiuolo F; Reichardt JK
Pharmacogenomics; 2001 Feb; 2(1):65-72. PubMed ID: 11258198
[TBL] [Abstract][Full Text] [Related]
8. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6.
Degeorges A; Tatoud R; Fauvel-Lafeve F; Podgorniak MP; Millot G; de Cremoux P; Calvo F
Int J Cancer; 1996 Oct; 68(2):207-14. PubMed ID: 8900430
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta 1 and androgen receptors in prostate neoplasia.
Cardillo MR; Petrangeli E; Salvatori L; Ravenna L; Di Silverio F
Anal Quant Cytol Histol; 2000 Oct; 22(5):403-10. PubMed ID: 11064817
[TBL] [Abstract][Full Text] [Related]
10. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
11. Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue.
Bjelfman C; Söderström TG; Brekkan E; Norlén BJ; Egevad L; Unge T; Andersson S; Rane A
J Clin Endocrinol Metab; 1997 Jul; 82(7):2210-4. PubMed ID: 9215296
[TBL] [Abstract][Full Text] [Related]
12. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
13. Microautoradiographic quantitation of vascular endothelial growth factor mRNA levels in human prostate specimens containing normal and neoplastic epithelium.
Woessner RD; Wright PS; Loudy DE; Wallace CD; Montgomery LR; Nestok BR
Exp Mol Pathol; 1998; 65(1):37-52. PubMed ID: 9613925
[TBL] [Abstract][Full Text] [Related]
14. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma.
Olapade-Olaopa EO; MacKay EH; Taub NA; Sandhu DP; Terry TR; Habib FK
Clin Cancer Res; 1999 Mar; 5(3):569-76. PubMed ID: 10100708
[TBL] [Abstract][Full Text] [Related]
15. Expression and significance of S100P, CD147, and OCT4 in different prostate cancer tissue TNM stages.
Wang Q; Zhang JG; Wang W
Genet Mol Res; 2015 Jun; 14(2):6844-51. PubMed ID: 26125892
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
[TBL] [Abstract][Full Text] [Related]
17. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue.
Wang Y; Hayward SW; Donjacour AA; Young P; Jacks T; Sage J; Dahiya R; Cardiff RD; Day ML; Cunha GR
Cancer Res; 2000 Nov; 60(21):6008-17. PubMed ID: 11085521
[TBL] [Abstract][Full Text] [Related]
18. Gray level entropy matrix is a superior predictor than multiplex ELISA in the detection of reactive stroma and metastatic potential of high-grade prostatic adenocarcinoma.
Jia X; Sun Y; Wang B
IUBMB Life; 2014 Dec; 66(12):847-53. PubMed ID: 25631296
[TBL] [Abstract][Full Text] [Related]
19. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
[TBL] [Abstract][Full Text] [Related]
20. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease.
Silver RI; Wiley EL; Davis DL; Thigpen AE; Russell DW; McConnell JD
J Urol; 1994 Aug; 152(2 Pt 1):433-7. PubMed ID: 7516976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
